Page 2 - ஆர்ட்டியோஸ் பார்மா வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Novartis AG - Consensus Indicates Potential 16 0% Upside - DirectorsTalk Interviews
directorstalkinterviews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from directorstalkinterviews.com Daily Mail and Mail on Sunday newspapers.
Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Polθ Polymerase Inhibitor in Nature Communications
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Arix Bioscience PLC: Artios announces collaboration with Novartis to create next generation DDR cancer therapies
DJ Artios announces collaboration with Novartis to create next generation DDR cancer therapies
Arix Bioscience PLC (ARIX)
Artios announces collaboration with Novartis to create next generation DDR cancer therapies
07-Apr-2021 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=
Arix Bioscience plc
Artios announces collaboration with Novartis to create next generation DDR cancer therapies - Artios to receive USD20 million up-front payment in addition to near term research funding to support the
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies
Artios Pharma, Inc.April 7, 2021 GMT
Novartis to leverage Artios’ discovery platform to identify DDR targets for use with Novartis’ proprietary radioligand therapies.
Artios to receive US$20 million up-front payment in addition to near term research funding to support the collaboration.
Artios eligible to receive up to $1.3 billion in discovery, development, regulatory and sales-based milestones in addition to royalty payments.
CAMBRIDGE, United Kingdom and NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company exploiting synthetic lethality to develop a broad pipeline of precision medicines for the treatment of cancer, today announced a global research collaboration with Novartis to discover and validate next generatio